Considerations in the pharmacoeconomics of dry eye.
Dry eye disease diminishes the quality of patients' lives and drives utilization of health care resources. Until recently, all treatments for dry eye have been palliative. A new treatment, cyclosporine A ophthalmic emulsion, addresses the disease's underlying causes. It warrants pharmacoeconomic analysis to determine its place in managed care.
Hirsch
Jan D
JD
Prescription Solution, Cost Mesa, Calif., USA.
D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D016572:Cyclosporine / Q000191:economics / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D017850:Economics, Pharmaceutical; D004655:Emulsions; D005260:Female; D006801:Humans; D008297:Male; D008329:Managed Care Programs / Q000191:economics*; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000191:economics / Q000627:therapeutic use; D010166:Palliative Care; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D004655:Emulsions; D009883:Ophthalmic Solutions; D016572:Cyclosporine